Compare NTLA & PAYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | PAYO |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | 2540 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2016 | N/A |
| Metric | NTLA | PAYO |
|---|---|---|
| Price | $17.38 | $7.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 8 |
| Target Price | ★ $20.02 | $7.69 |
| AVG Volume (30 Days) | 6.7M | ★ 12.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | $7.15 |
| Revenue Next Year | $62.75 | $10.28 |
| P/E Ratio | ★ N/A | $30.36 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $4.08 |
| 52 Week High | $28.24 | $7.67 |
| Indicator | NTLA | PAYO |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 76.74 |
| Support Level | $11.73 | $5.64 |
| Resistance Level | $27.61 | N/A |
| Average True Range (ATR) | 1.21 | 0.07 |
| MACD | 0.28 | -0.03 |
| Stochastic Oscillator | 84.38 | 87.50 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.